logo

Intra-Cellular Therapies, Inc. (ITCI)



Trade ITCI now with
  Date
  Headline
10/17/2018 8:08:02 AM Intra-Cellular Therapies To Present Results From ITI-214 Phase 1/2 Clinical Trial In Patients With Parkinson’s Disease
9/28/2018 7:08:21 AM Intra-Cellular Therapies Completes Submission Of NDA For Lumateperone For Schizophrenia
9/25/2018 7:04:58 AM Intra-Cellular Therapies Appoints Michael Olchaskey As SVP, Head Of Regulatory Affairs
8/2/2018 7:15:34 AM Intra-Cellular Therapies Q2 Net Loss $37.4 Mln Or $0.68/Shr Vs Loss Of $17.8 Mln Or $0.41/Shr Last Year
7/23/2018 7:05:47 AM Intra-Cellular Therapies Publishes Report Describing Mechanism Of Action Of PDE Type 1 Inhibitor, ITI-214
6/6/2018 7:07:15 AM Intra-Cellular Therapies Begins Rolling Submission Of NDA For Lumateperone For Treatment Of Schizophrenia
5/29/2018 8:07:12 AM Intra-Cellular Therapies Announces Presentations On Lumateperone At ASCP Annual Meeting
5/3/2018 7:22:23 AM Intra-Cellular Therapies Q1 Net Loss $35.5 Mln Or $0.65/Shr Vs Loss Of $26.9 Mln Or $0.62/Shr Last Year
3/13/2018 7:36:27 AM Intra-Cellular Therapies Announces Positive Pre-NDA Meeting With FDA For Lumateperone For Schizophrenia
3/1/2018 7:21:58 AM Intra-Cellular Therapies Q4 Net Loss $30.2 Mln Or $0.56/Shr Vs Net Loss Of $27.5 Mln Or $0.64/Shr Last Year
2/8/2018 6:14:21 AM RBC Capital Markets Starts Intra-Cellular Therapies, Inc. (ITCI) At Outperform With $33 Price Target
12/7/2017 8:05:45 AM Intra-Cellular Therapies Presents Data On Lumateperone, ITI-214 And ITI-333
11/20/2017 7:03:02 AM Intra-Cellular Therapies Gets FDA Fast Track Designation For Lumateperone For Treatment Of Schizophrenia
11/14/2017 8:10:11 AM Intra-Cellular Therapies Presents Data On Mechanism Of Action Of Lumateperone And ITI-214
11/8/2017 7:33:56 AM Intra-Cellular Therapies Q3 Net Loss $22.9 Mln Or $0.53/shr Vs Loss Of $30.3 Mln Or $0.70/shr Last Year
10/3/2017 8:04:45 AM Intra-Cellular Therapies Begins Enrollment Of Clinical Trial Evaluating ITI-214 In Patients With Parkinson’s Disease